{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-130449","form_type":"8-K","ticker":"EIKN","cik":"0001861123","company_name":"Eikon Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.592859+00:00","generated_at":"2026-05-15T08:26:47.848449+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eikon Therapeutics reports Q4/FY2025 net loss $79.7M/$333.6M; IPO raised $381M","bullets":["Net loss attributable to common stockholders was $79.7M in Q4 2025 and $333.6M for full year 2025.","Cash, cash equivalents and marketable securities $336M as of Dec 31, 2025; added $381.2M from IPO in Feb 2026.","Completed enrollment of TeLuRide-005 Phase 2 trial of EIK1001 in first-line stage 4 NSCLC; data expected 2H 2026.","R&D expenses $65.2M in Q4 2025 (+21% YoY); $250.3M for FY2025 (+22% YoY).","Elected David W. Meline (former CFO of Moderna, Amgen, 3M) as independent director in December 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-130449","json":"https://secwatch.observer/filing/0001193125-26-130449.json","markdown":"https://secwatch.observer/filing/0001193125-26-130449.md","text":"https://secwatch.observer/filing/0001193125-26-130449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526130449/0001193125-26-130449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526130449/d244624d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:26:47.848449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c24c89ecf5fc940799d656eca01b22ffa76976f4","claim":"Eikon Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2025 results: net income Net loss attributable to common stockholders was $79.7 million for the fourth quarter of 2025.","evidence_excerpt":"On March 30, 2026, Eikon Therapeutics, Inc. issued a press release announcing clinical and corporate updates and its financial results for the three months and full year ended December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526130449/0001193125-26-130449-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2025"},{"label":"Net income","value":"Net loss attributable to common stockholders was $79.7 million for the fourth quarter of 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}